Last reviewed: June 21, 2026
Last updated: June 21, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide's transition from diabetes management to weight loss represents one of modern medicine's most significant clinical pivots. The medication, originally developed by Novo Nordisk for type 2 diabetes control, demonstrated such powerful appetite-suppressing effects in trials that the FDA expanded its use for chronic weight management in November 2021. Today, compounded versions through PlexusDx bring this GLP-1 therapy to patients across all 50 states at a fraction of brand-name costs.
The Original Purpose: Semaglutide as a Diabetes Treatment
Semaglutide first received FDA approval in December 2017 under the brand name Ozempic, exclusively for adults with type 2 diabetes. The medication mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar and signals satiety to the brain. Clinical trials for diabetes showed weight loss as an unexpected but consistent side effect—patients lost an average of 5 to 8 pounds alongside improved glucose control.
Researchers and physicians noticed that obese and overweight patients with diabetes experienced particularly pronounced weight reduction. This observation sparked interest in studying semaglutide's metabolic effects beyond glucose management. Patient reports of reduced hunger and changed food preferences became increasingly common as the medication gained wider use in endocrinology practices.
The STEP Trials: Clinical Evidence for Weight Loss
Between 2018 and 2020, Novo Nordisk conducted the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program, which fundamentally changed how the medical community understood this drug's potential. The STEP 1 trial enrolled 1,961 adults with obesity or overweight status and at least one weight-related medical condition, none having type 2 diabetes. Participants receiving the 2.4-mg weekly dose lost an average of 34 pounds over 68 weeks, compared to 6 pounds in the placebo group—a 15% reduction in body weight.
STEP 2, STEP 3, and STEP 4 trials reinforced these findings across diverse populations, including those with existing cardiovascular disease and individuals who had previously attempted weight loss medications. The consistency of results across different demographics and baseline health statuses established semaglutide as a credible weight-loss intervention. These trials demonstrated that the medication's benefits extended beyond simple appetite suppression, influencing metabolic rate and energy expenditure at the cellular level.
FDA Approval for Weight Management in 2021
The FDA granted approval for semaglutide specifically for chronic weight management on November 4, 2021, under the brand name Wegovy. This approval created a new category for the medication: a GLP-1 receptor agonist indicated for long-term weight loss in adults with obesity or overweight status who have at least one weight-related condition. The regulatory decision represented a watershed moment, officially recognizing that semaglutide's weight-loss effects were not merely a side benefit but a primary therapeutic action.
The approval came with important clinical guidance: Wegovy was recommended for use with lifestyle modifications including reduced-calorie diet and increased physical activity. The FDA labeled it for chronic use rather than short-term weight loss, acknowledging that sustained therapy was necessary for sustained results. Coverage and availability expanded rapidly, though cost barriers emerged as insurers initially limited reimbursement.
Compounded Semaglutide and Modern Access
As demand for semaglutide grew and brand-name prices remained high, compounded versions emerged through licensed 503A pharmacies, offering patients a more affordable pathway to GLP-1 therapy. PlexusDx partners with 503A compounding facilities to deliver sterile, compounded semaglutide injections starting at $149 per month—a significant cost reduction compared to brand-name Wegovy, which often exceeds $1,300 monthly. Compounded medications maintain the same active pharmaceutical ingredient and injection mechanism as branded formulations while removing markup layers.
PlexusDx serves all 50 states without requiring insurance coverage, making semaglutide accessible to uninsured and self-pay patients. The platform also qualifies compounded semaglutide for HSA and FSA accounts, providing tax-advantaged payment options. For patients seeking personalized dosing and genetic insight, PlexusDx offers the Precision Peptide Genetic Test at $99 as an add-on, mapping 49 peptides across 14 metabolic pathways to optimize individual treatment response.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What year did doctors start using semaglutide for weight loss rather than diabetes?
Clinical interest in semaglutide for weight loss grew during 2017-2020 as diabetes patients reported significant weight reduction, but formal FDA approval for weight management came in November 2021 under the Wegovy brand. Between approval and now, compounded versions through licensed 503A pharmacies became available, expanding access while maintaining efficacy and safety standards.
How much weight did people lose in the clinical trials that led to FDA approval?
The STEP 1 trial showed that participants receiving 2.4-mg weekly semaglutide lost an average of 34 pounds over 68 weeks, achieving roughly 15% total body weight reduction. The placebo group lost only 6 pounds, demonstrating that semaglutide's effect was substantially greater than lifestyle changes alone.
How much does PlexusDx compounded semaglutide cost each month?
PlexusDx compounded semaglutide injections start at $149 per month on our entry-level tier, with prices remaining flat regardless of dose escalation—your dose may need to go up, but your price won't. The medication qualifies for HSA and FSA accounts and is available without insurance across all 50 states.
Is compounded semaglutide as safe and effective as brand-name Wegovy?
Compounded semaglutide contains the identical active pharmaceutical ingredient as Wegovy and is prepared in licensed 503A compounding pharmacies under strict pharmaceutical standards. Both formulations work through the same GLP-1 receptor mechanism; the primary difference is cost and accessibility rather than safety or efficacy profile.
Can genetic testing help me know if semaglutide will work better for me?
Yes—PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) analyzes key variants like GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 across 14 metabolic pathways to predict your individual response to GLP-1 therapy. This personalized insight helps optimize your dose and treatment strategy based on your peptide biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Quickly Do Side Effects Happen From Ozempic?
What is the Best Time to Take Ozempic for You?